Foundation mixing technology of cells and mushrooms C. albicans and C. tropicalis

M. V. Rybalkin, L. S. Strelnikov, O. P. Strilets

Abstract


Topicality. Number of patients with candidiasis grow every year, and for its treatment doctors the same antimycotics for many years, the agent gradually loses sensitivity for them. Nowadays abroad, actively conducted research to develop vaccines against candidiasis.
Aim. Tojustify the technology mixing cell fungi C. albicans and C. tropicalis.
Materials and methods. For the ultrasonic mixing used ultrasonic intensity setting at 0.3, 0.5 and 0.7 W/cm2and exposure 5, 10 and 15 min. For the mechanical mixing used the device using mixing with an electric mixer with a speed of 50, 70 and 100 rev/min for 5, 10 and 15 min. After having finished the mixing process, 1 ml of the suspension was selected in each case, which was diluted in 106 and plated on medium Hissa in the same volume of 1 ml.
Results and discussion. The obtained results were showed that the use of ultrasound in investigating parameters have not provide uniform mixing cell fungi C. albicans and C. tropicalis. The using of mixer at rotation speed of 100 t/min for 15 min exposure amount CFU mushrooms C. albicans and C. tropicalis was almost identical, that is indicated a complete and uniform mixing of cells of fungi.
Conclusions. The result of experiment has found the using of mixer with speed of 100 rev/min for 15 min in 100 ml t/min by mixing 50 ml suspension of cell C. albicans fungi and 50 ml suspension of cell mushrooms C. tropicalis provides
the best results.


Keywords


candidiasis; antigen; vaccine; mix; technology

References


Kullberg, B. J. Invasive Candidiasis / B. J. Kullberg, M. C. Arendrup // New Engl. J. Med. – 2015. – Vol. 373. – P. 1445–1456.

Candidemia and invasive candidiasis in adults: A narrative review / S. Antinori, L. Milazzo, S. Sollima et al. // NCBI. – 2016. – № 34. – P. 21–28.

Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America / P. G. Pappas,

C. A. Kauffman, D. R. Andes et al. // Clin. Infect Dis. – 2016. – 62:e1.

Маркетингові дослідження ринку протигрибкових лікарських засобів для місцевого застосування / О. І. Тихонов, О. Є. Фролова,

О. П. Гудзенко, С. В. Барнатович // Соціальна фармація в охороні здоров’я. – 2015. – Т. 2, № 2. – С. 77–81.

Cassone, A. Development of vaccines for Candida albicans: fighting a skilled transformer / A. Cassone // Nature Rev. Microbiol. – 2013. – Vol. 11.

– P. 884–891.

Vaccines in the treatment of invasive candidiasis / X. Wang, X. Sui, L. Yan et al. // Virulence. – 2015. –Vol. 6, № 4. – P. 309–315.

Рибалкін, М. В. Обґрунтування оптимального методу інактивації клітин грибів Candida albicans та Candida tropicalis / М. В. Рибалкін //

Фармаком. – 2014. – № 2. – С. 30–33.

Визначення здатності інактивованих клітин грибів Candida albicans та Candida tropicalis окремо формувати імунітет проти кандидозної

інфекції / М. В. Рибалкін, Н. І. Філімонова, О. П. Стрілець, Л. С. Стрельников // Укр. біофармац. журн. – 2014. – Т. 31, № 2. – С. 8–12.

Краснопольский, Ю. М. Фармацевтическая биотехнология. Технология производства иммунобиологических препаратов / Ю. М. Крас-

нопольский, М. И. Борщевская. – Х. : НТУ «ХПИ», 2009. – 352 c.

Crommelin, D. J. A. Pharmaceutical biotechnology: fundamentals and applications. 4th ed. / D. J. A. Crommelin, R. D. Sindelar, B. Meibohm. – New

York : Springer, 2013. – 490 p.


GOST Style Citations


1. Campion, E. W., Kullberg, B. J., Arendrup, M. C. (2015). Invasive Candidiasis. New England Journal of Medicine, 373(15), 1445–1456. doi: 10.1056/nejmra1315399

2. Antinori, S., Milazzo, L., Sollima, S., Galli, M., Corbellino, M. (2016). Candidemia and invasive candidiasis in adults: A narrative review. European
Journal of Internal Medicine, 34, 21–28. doi:10.1016/j.ejim.2016.06.029

3. Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky–Zeichner et al. (2015). Clinical Practice Guideline for the Management
of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases, 62 (4). doi:10.1093/cid/civ933

4. Tykhonov, O. I., Frolova, O. Ye., Hudzenko, O. P., Barnatovych, S. V.(2015). Social pharmacy in health care, 2 (2), 77–81.

5. Cassone, A. (2013). Development of vaccines for Candida albicans: fighting a skilled transformer. Nature Reviews Microbiology, 11(12), 884–891. doi: 10.1038/nrmicro3156

6. Wang, X., Sui, X., Yan, L., Wang, Y., Cao, Y., Jiang, Y. (2015). Vaccines in the treatment of invasive candidiasis. Virulence, 6 (4), 309–315. doi: 10.4161/21505594.2014.983015

7. Rybalkin, M. V. (2014). Farmakom, 2, 30–33.

8. Rybalkin, M. V., Filimonova, N. I., Strilets’, O. P., Strel’nykov L. S. (2014). Ukrains’kyi biofarmatsevtychnyi zhurnal – Ukrainian biopharmaceutical journal, 31 (2), 8–12.

9. Krasnopol’skyi, Yu. M., Borshchevskaia, M. Y. (2009). Farmatsevtycheskaia biotekhnolohiia. Tekhnolohiia proizvodstva immunobiolohicheskikh preparatov.
Kharkov: NTU «KhPI», 352.

10. Crommelin, D. J. A., Sindelar, R. D., Meibohm, B. (2013). Pharmaceutical biotechnology: fundamentals and applications. (4th ed). New York: Springer,
490. doi: 10.1007/978-1-4614-6486-0





DOI: https://doi.org/10.24959/ubphj.17.98

Abbreviated key title: Ukr. bìofarm. ž.

ISSN 2519-8750 (Online), ISSN 2311-715X (Print)